hotspot -WSS

hotspot

author：comprehensive 2025-09-28 02:30:38 - browse：299

Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million in a Series C funding round from investors including pharma company Amgen and the VC arm of AI giant NVIDIA.

Generate was founded in 2018 by venture-creation firm Flagship Pioneering to use machine learning algorithms to identify antibodies, peptides, cell therapies, and other medicines. It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment.

The biotech, which is based in Somerville, Mass., has big plans for the next couple of years: It has another 15 drug candidates in the works and plans to introduce 10 more annually, CEO Mike Nally told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： No plane should take off without an EpiPen onboard

hotspot

WSS

iTeos Therapeutics debuts first data on TIGIT

Prosthetic arm enables patients to feel the objects they grip

Prosthetic arm enables patients to feel the objects they grip

iTeos Therapeutics debuts first data on TIGIT

Akili, maker of video game for ADHD, to be acquired for 34 million

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

knowledge

hotspot

focus

How to save PrEP access — and even expand it

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

What does generative AI mean for health care? We asked experts

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Jerome Adams on the need for new antivirals for Covid

Focused ultrasound for uterine fibroids: an uphill battle

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

EQRx, failed developer of low

At least 13 dead in Texas as scorching temps continue

iTeos Therapeutics debuts first data on TIGIT

focus

EQRx, failed developer of low

No plane should take off without an EpiPen onboard

Pence says 'crackpot lawyers' told Trump what he wanted to hear

David Sabatini, ex

iTeos Therapeutics debuts first data on TIGIT

Startling documents reveal new facets of Sacklers' opioid empire

knowledge

hotspot

knowledge

explore